The U.S. Food and Drug Administration (FDA) has approved a clinical trial for a cannabidiol (CBD)-based drug to treat opioid use disorder.
The trial will be led by UCLA professors Edythe London and Richard De La Garza II. In a statement, London said the “clinical trial is a key milestone for our ongoing research into therapeutic alternatives for opioid use disorder and reversal of the effects of the opioid epidemic.”
A study published last year in the journal Applied Health Economics and Health Policy found that cannabis legalization has led to a “marked decline” in the volume of opioids prescribed across Canada.
The study tracked total opioid prescribing volumes and expenditures prior to and following cannabis legalization by sifting through national prescription claims data from private and public payers between January 2016 and June 2019.
Researchers found that, following legalization, total monthly opioid
Read full article on The Growth Op
